The first transplant using cord blood-derived hematopoietic stem cells was performed in October 1988. Since that year, remarkable achievements have been made in terms of research into umbilical cord blood-derived hematopoietic and progenitor cells. More than 40,000 UCB transplants (UCBTs) have been performed across different geographies of the world, in both children and adults, to treat diseases that include hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. [Read more…]
What Did 2025 Teach Us About Stem Cell Innovation and Market Dynamics?
What has 2025 taught us about stem cell innovation and market dynamics? For cell therapy professionals, 2025 was a defining year, not because it produced a single breakthrough, but because it clarified how the future of the sector will actually be built. Instead of chasing headlines, companies focused on solving the structural barriers that have held the field back for more than a decade.
New data, maturing pipelines, and shifting investment patterns brought fresh realism to a sector often driven more by optimism than operational readiness. Above all, 2025 revealed the difference between technologies that promise transformation and infrastructure that can actually deliver it. [Read more…]
Power of Stem Cell Injections for Plantar Fasciitis Treatment
With existing treatments having limited success at healing the connective tissue disorders, regenerative medicine is preparing to fill the void. When it comes to plantar fasciitis treatment, could stem cell injections represent a low-awaited cure?
In this article:
Top Stem Cell Applications in 2026: How Stem Cells Are Transforming Medicine Today
Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types. Stem cell research and experimentation have been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly.
In this article:
Novo Nordisk Ends $598M Heartseed Partnership to Refocus Strategic Priorities
Sadly, Novo Nordisk has ended its $598 million collaboration with Tokyo-based biotech Heartseed, marking a major shift in its approach to regenerative medicine and iPSCs, specifically. The cancelled partnership, originally launched in 2021, was focused on developing an allogeneic induced pluripotent stem cell (iPSC)-derived therapy for heart failure called “HS-001”.
Novo’s decision to terminate the deal, announced by Heartseed in a securities filing this week, was attributed to “strategic reviews and business shifts” under the company’s new CEO, Mike Doustdar. The move ends a four-year partnership that once represented a bold leap into regenerative medicine for Novo Nordisk. [Read more…]
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 339
- Next Page »